Immuron

97 articles about Immuron

• Immuron Partners with CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of Defense

  6/19/2020

  Immuron Limited, an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to provide shareholders with an update on the progress made to date on the company’s research collaboration with the Naval Medical Research Center previously announced in October 2019.

• US DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute Infectious Diarrhea

  6/9/2020

  Immuron Limited, an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to provide shareholders with an update on the company’s research collaboration with the Naval Medical Research Center to develop and clinically evaluate a new therapeutic against campylobacter and ETEC.

• Immuron Board Relinquish Cash Payment of Fees

  4/28/2020

  Immuron Limited, an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, announced that the cash payments of Board fees will be suspended and replaced with Immuron stock.

• Immuron North American Travelan® Sales Up 95%, Global Sales Up 60%

  4/20/2020

  Immuron Limited announced the sales results of its commercially available and over-the-counter gastrointestinal and digestive health immune supplement Travelan® for the third quarter of the fiscal year 2020 ending on March 31, 2020.

• Resignation of CEO & Director and cost cutting amidst COVID-19

  3/25/2020

  The Directors and Management of Immuron wish to provide an update to the market regarding the current and future impact of COVID-19 on the Company. The World is in the midst of an unprecedented health crisis as a result of the COVID-19 pandemic. An entirely new political, social, and economic reality has emerged and will continue to evolve. The consequences of this altered reality will have serious ramifications for many companies and

• 

  Biopharma Industry News for March 25: Update on the Novel Coronavirus

  3/25/2020

  A summary of daily biopharma industry news. Please check out stories that are trending on March 25, 2020.

• North American Travelan® sales up 98% in the first half of FY20

  1/28/2020

  Immuron Limited announced the sales results of its commercially available and over-the-counter gastrointestinal and digestive health supplement Travelan® for the first half of fiscal year 2020 ending on December 31, 2019.

• Immuron CEO Dr. Gary S. Jacob to Present at Biotech Showcase Conference on January 13, 2020

  1/8/2020

  Immuron Limited, an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, announced that CEO Dr. Gary S. Jacob will present at the Biotech Showcase Conference on Monday, January 13, 2020 at the Hilton Union Square hotel in San Francisco.

• Immuron Plans Phase 3 trial for IMM-124E to Prevent Travelers’ Diarrhea

  11/21/2019

  Immuron completes first meeting with FDA on development of IMM-124E as product to specifically prevent Travelers’ Diarrhea (TD)

• Immuron: Travelan Revenue Grows Significantly in U.S. and Australia

  2/16/2018

  Travelan experienced strong sales growth in both the U.S. and Australian markets throughout the first half of the 2018 financial year.

• Immutep Limited Announces Milestone Payment From Chinese Partner EOC Pharma

  2/1/2018

  The milestone payment of US$1 million relates to the clinical development of eftilagimod alpha in China and follows the granting of EOC Pharma’s Investigational New Drug (IND) application in China, as outlined in Immutep’s December 12, 2017 Operational Update.

• Immuron Enrolls First Patients in Clinical Study of IMM-529 for Treatment of Clostridium Difficile Infection (CDI)

  1/31/2018

  The Immuron CDI clinical study is a Phase I/II placebo-controlled study focusing on the safety, tolerability, and preliminary efficacy of IMM-529.

• U.S. Defense Reports Broad Travelan Reactivity to 180 Pathogenic Bacteria Including Camylobacter and Shigella

  1/29/2018

  The primary goal of this program was to investigate Travelan immunological reactivity with pathogenic bacteria including Campylobacter, Enterotoxigenic Escherichia coli (ETEC) and Shigella.

• Immuron to Receive $2.16M R&D Tax Concession Refund

  1/24/2018

  This refund reflects the more than $4.6M investment the Company made in its research and development programs during the 2017.

• Van Leeuwenhoeck Institute Updates Immuron Research Coverage

  11/22/2017

  The Van Leeuwenhoeck Institute has published an updated Equity Analyst Research Report on the Company and its R&D programs.

• Immuron Granted U.S. Patent for NASH Treatment

  11/15/2017

  The patent comprises of a total of ten allowed claims, and is principally directed to a method of treating non-alcoholic steatohepatitis (NASH) with a colostrum-based composition, as developed by Immuron.

• Immuron Successfully Completes NASH Phase II Clinical Study Milestone

  11/9/2017

  The last patient in the Company's NASH clinical study conducted the final scheduled visit on October 9, following a 28-week study period.

• Immuron’s Travelan Experiences Strong Q1 FY2018 Sales Growth

  11/8/2017

  Travelan U.S. experienced a 197% increase in sales compared to Q1 2017.

• Immuron Highlights Market Opportunity Following Recent Studies on Antibiotic Correlation to C. Difficile Infections

  10/17/2017

  One study performed by the Minnesota Department of Health on antibiotic prescribing for dental procedures in community-associated clostridium difficile cases, which was presented at ID Week 2017.

• Immuron Highlights Recent Milestones In Quest To Effectively Treat Multiple Forms Of Fatty Liver Diseases That Impact Millions

  9/19/2017